ArticleNPJ breast cancer2022

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.